Subscribe: Market Wire - Pharmaceuticals and Biotech: Equipment and Supplies
http://img.marketwire.com/rss/mwPBES.rss
Preview: Market Wire - Pharmaceuticals and Biotech: Equipment and Supplies

Marketwired - Equipment and Supplies



Marketwired - Equipment and Supplies



Last Build Date: Tue, 20 Feb 2018 11:27:40 EST

Copyright: Copyright: (C) Marketwired
 



Relevium Commences Trading on OTCQB

Tue, 20 Feb 2018 10:56:23 EST

MONTREAL, QUEBEC--(Marketwired - Feb. 20, 2018) - Relevium Technologies Inc. (TSX VENTURE:RLV)(OTCQB:RLLVF)(FRANKFURT:6BX) (the "Company" or "Relevium"), is pleased to announce that it has commenced trading on the OTCQB under the symbol RLLVF




ORYZON Reports Financial Results and Corporate Update for the 4th Quarter and Year Ended December 31, 2017

Tue, 20 Feb 2018 08:08:10 EST

MADRID, SPAIN and CAMBRIDGE, MA--(Marketwired - February 20, 2018) - Oryzon Genomics, S.A. (ISIN Code: ES0167733015) (MAD: ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has reported today financial results for the fourth quarter of 2017 and provided an update on the Company's recent developments.




Changes to its Board of Directors: Oryzon revamps its Board with an expert in Biomedicine and Epigenetics in the US industry

Tue, 20 Feb 2018 08:00:00 EST

José Carlos Gutiérrez-Ramos, President and CEO of Synlogic joins as Independent Director

NAJETI family fund steps down




Pieris Pharmaceuticals to Present at the RBC Capital Markets 2018 Global Healthcare Conference

Mon, 19 Feb 2018 08:30:00 EST

BOSTON, MA--(Marketwired - February 19, 2018) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that members of the management team will present at the RBC Healthcare Conference on Thursday, February 22, 3:35 pm EST at The New York Palace Hotel, New York City. A webcast of the Company's presentation will be available at this link.




Pieris Pharmaceuticals Announces Closing of Public Offering and Exercise of Underwriters' Option to Purchase Additional Shares

Fri, 16 Feb 2018 17:36:17 EST

BOSTON, MA--(Marketwired - February 16, 2018) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced today the closing of its previously announced underwritten public offering and the exercise in full of the underwriters' option to purchase additional shares. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Pieris, are $50.6 million. 6,325,000 shares of common stock at a public offering price of $8.00 per share were issued and sold in the offering, which includes 825,000 shares issued upon the exercise of the underwriters' option to purchase additional shares, less the underwriting discounts and commissions.




Relevium Announces 2018 AGM Results

Fri, 16 Feb 2018 15:38:03 EST

MONTREAL, QUEBEC--(Marketwired - Feb. 16, 2018) - Relevium Technologies Inc. (TSX VENTURE:RLV)(OTCQB:RLLVF)(FRANKFURT:6BX) (the "Company" or "Relevium"), is pleased to announce the positive results from its annual and special meeting held on February 15, 2018 in Montréal, Canada (the "AGM").




Moleculin Announces Pricing of $9 Million Registered Direct Offering

Fri, 16 Feb 2018 08:28:56 EST

HOUSTON, TX--(Marketwired - February 16, 2018) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that it has entered into a definitive agreement with institutional investors for a registered direct offering of securities with gross proceeds of approximately $9 million. The closing of the offering is expected to take place on or about February 21, 2018, subject to the satisfaction of customary closing conditions.




Moleculin Announces Breakthrough Discovery of a New Molecule for Cancer Treatment

Thu, 15 Feb 2018 08:30:00 EST

Cutting Edge Science Suggests New Molecule Is Capable of Shutting Down Tumor Activity




Pieris Pharmaceuticals Announces Pricing of its Public Offering

Wed, 14 Feb 2018 00:27:18 EST

BOSTON, MA--(Marketwired - February 14, 2018) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced today the pricing of its previously announced underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $8.00 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Pieris, are expected to be $44.0 million. In addition, Pieris has granted the underwriters a 30-day option to purchase up to 825,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about February 16, 2018, subject to customary closing conditions.




Pieris Pharmaceuticals Announces Public Offering of Common Stock

Tue, 13 Feb 2018 16:01:00 EST

BOSTON, MA--(Marketwired - February 13, 2018) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. Pieris intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in the offering at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering will be sold by Pieris.